Tapimmune Announces Development Of Advanced Immunotherapeutic Vaccine Expression And Delivery System
October 9, 2013, Seattle, WA. TapImmune is pleased to announce development of a revolutionary cost effective immunotherapeutic vaccine expression and delivery system.
The novel platform is termed TapImmune’s PolyStart™ technology and has been strategically designed to directly enhance the immune system’s ability to stimulate either or BOTH cytotoxic killer and helper T-cell reactive proprietary peptides, known and expected to be associated with one, or more importantly, ANY cancer, infectious disease or bio-threat.
Specifically the PolyStart and PAA (Peptide Antigen Array) technologies are straight forwardly and easily managed as a rapid versatile plugin-and-play system meaning that they can be configured to produce peptides for any desired pathogen. We believe that our combined PolyStart and PAA technologies provide the highest level of expression of any comparable system deployed to date. Our technology platform is functionally distinct from conventional single target immunotherapies such as Herceptin, and can be administered to a much broader patient population.
Please see full Press Release here.
Follow TapImmune on LinkedIn http://www.linkedin.com/company/tapimmune-inc